Dr Lal PathLabs Limited has made a further investment in its wholly owned subsidiary, PathLabs Unifiers Private Limited (PUPL), to facilitate the acquisition of the remaining 30% equity stake in CentraPath Labs Private Limited (CPL). The move aims to consolidate ownership of CPL, making it a wholly owned subsidiary of PUPL.

The company disclosed this development on October 12, 2026, in a filing with the National Stock Exchange and BSE. The investment was made by subscribing to equity shares of PUPL. This action falls under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Transaction Details

The acquisition of the remaining stake in CPL is structured as a cash consideration. The total cost of acquisition or the price at which the shares are acquired is stated as not exceeding ₹30.3 crore. The transaction was completed immediately, with no pending governmental or regulatory approvals required.

Subsidiary Profile

PathLabs Unifiers Private Limited, the intermediary entity through which the acquisition is routed, operates in the healthcare and diagnostics services sector. Incorporated on December 12, 2018, in Delhi, PUPL serves as a wholly owned subsidiary of Dr Lal PathLabs. The company reported stable turnover figures over the last three fiscal years.

Regulatory and Related Party Status

Since PUPL is a wholly owned subsidiary of Dr Lal PathLabs, the proposed subscription of shares constitutes a related party transaction. The company confirmed that the transaction will be conducted on an arm's length basis. The disclosure highlights that the primary objective is to fund PUPL's acquisition of the minority stake in CPL, thereby streamlining the corporate structure within the group's diagnostics operations.

Dr. Lal PathLabs Limited received intimation on October 7, 2026 of an Income Tax Department appeal filed before the Income Tax Appellate Tribunal, New Delhi, against an appellate order for Assessment Year 2022-23.

Background of the tax dispute

The matter originates from an assessment order received by the company from the Income Tax Department, followed by an appellate order issued in favour of the company. The company had previously disclosed these developments through letters dated April 1, 2024 and July 17, 2026, respectively, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Income Tax Department has now challenged the appellate order before the Income Tax Appellate Tribunal, New Delhi. The appeal was filed against the order of the Commissioner of Income Tax (Appeals), Income Tax Department, which had allowed relief to the company on disallowances of ESOP expenses.

Key details of the appeal

The following table summarises the material particulars of the intimation as disclosed by the company:

Company's assessment of impact

Dr. Lal PathLabs has stated that it does not reasonably expect the outcome of the appeal to have any material impact on the company. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.